Tobias Neff, MD, University of Colorado Anschultz Medical Campus (IMAGE)

University of Colorado Anschutz

Tobias Neff, MD, University of Colorado Anschultz Medical Campus

Caption

Tobias Neff, MD, and colleagues implicate EZH2 in development of aggressive pediatric leukemia subtype, ETP-ALL, possibly leading to new treatments for the disease.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.